Cytogenetic and Molecular Genetic Abnormalities of CIITA Gene in Patients with Primary Mediastinal (Thymic) Large B-Cell Lymphoma

AUTOIMMUNE THROMBOCYTOPENIA

SA Kuznetsova, VL Surin, YaK Mangasarova, TYu Novikova, LA Grebenyuk, AU Magomedova, SK Kravchenko, OS Pshenichnikova, AM Sergeeva, TN Obukhova

National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Svetlana Aleksandrovna Kuznetsova, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; Tel.: +7(985)170-61-83; e-mail: svetakuznetsova83@mail.ru

For citation: Kuznetsova SA, Surin VL, Mangasarova YaK, et al. Cytogenetic and Molecular Genetic Abnormalities of CIITA Gene in Patients with Primary Mediastinal (Thymic) Large B-Cell Lymphoma. Clinical oncohematology. 2021;14(2):173–8. (In Russ).

DOI: 10.21320/2500-2139-2021-14-2-173-178

ABSTRACT

Background. Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is an aggressive malignant lymphoproliferative disease which accounts for 2–3 % of all non-Hodgkin’s lymphomas. In 40 % of PMBCL cases rearrangements of the MHC class II activator, i.e. CIITA gene, are observed. CIITA abnormalities lead to decreasing protein expression and surface expression of MHC class II, which results in lack of adaptive cell immunity targeted at tumor cells.

Aim. To assess the rate and spectrum of cytogenetic and molecular genetic abnormalities of CIITA gene in PMBCL patients.

Materials & Methods. The study enrolled 37 patients with diagnosed PMBCL: 10 men and 27 women aged 21–61 years (median of 31 years). Sanger sequencing was performed in 36 patients. In 20 patients CIITA/16p13.13 FISH and in 15 patients standard cytogenetic analysis were carried out.

Results. In 3 (8.3 %) out of 36 patients the sequencing method detected mutations impairing CIITA gene function, as well as microdeletion in exon 1, deletion and nucleotide substitution in a splice donor site. Multiple somatic variations in intron 1 were identified in 21 (58.3 %) patients: in 11 (52.4 %) cases there were deletions and single nucleotide variants (SNV); the other 10 (47.6 %) patients showed only SNVs. In 13 (61.9 %) out of 21 cases the abnormalities of promoter IV and/or alternative exon 1 were observed. In 5 (25 %) out of 20 patients the FISH assay identified CIITA gene translocation. Standard cytogenetic analysis detected complex karyotype in 7 (46.6 %) out of 15 patients. The comparison of data showed hypermutagenesis in 8 out of 10 patients with FISH-detected chromosome aberrations, and in 3 (37.5 %) of them complex karyotype aberrations were found as well.

Conclusion. Molecular genetic methods identified different somatic variations in CIITA gene affecting its functionally important regions, which can be of special interest for further studying the biology of tumors, including PMBCL.

Keywords: primary mediastinal (thymic) B-cell large cell lymphoma, CIITA, FISH, chromosomal aberrations, Sanger sequencing.

Received: December 15, 2020

Accepted: March 11, 2021

Read in PDF

Статистика Plumx английский

REFERENCES

  1. Cazals-Hatem D, Lepage E, Brice P, et al. Primary Mediastinal Large B-Cell Lymphoma A Clinicopathologic Study of 141 Cases Compared with 916 Nonmediastinal Large B-cell Lymphomas, a GELA (“Groupe d’Etude des Lymphomes de l’Adulte”) Study. Am J Surg Pathol. 1996;20(7):877–88. doi: 10.1097/00000478-199607000-00012.
  2. Мангасарова Я.К., Магомедова А.У. Нестерова Е.С. и др. Первые результаты терапии первичной медиастинальной В-крупноклеточной лимфомы по программе R-DA-EPOCH-21. Терапевтический архив. 2016;88(7):37–42. doi: 10.17116/terarkh201688737-42.
    [Mangasarova YaK, Magomedova AU, Nesterova ES, et al. Therapy for primary mediastinal large B-cell lymphoma in accordance with the R-DA-EPOCH-21 program: the first results. Terapevticheskii arkhiv. 2016;88(7):37–42. doi: 10.17116/terarkh201688737-42. (In Russ)]
  3. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659–69. doi: 10.1182/blood-2011-05-326538.
  4. Masternak K, Muhlethaler-Mottet A, Villard J, et al. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 2000;14(9):1156–66. doi: 10.1101/gad.14.9.1156.
  5. Scholl T, Mahanta SK, Strominger JL. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Proc Natl Acad Sci USA. 1997;94(12):6330–4. doi: 10.1073/pnas.94.12.6330.
  6. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54(4):307–14. doi: 10.1007/s00262-004-0593-x.
  7. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471(7338):377–83. doi: 10.1038/nature09754.
  8. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular. Blood. 2004;103(11):4251–8. doi: 10.1182/blood-2003-07-2365.
  9. Twa DDW, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062–5. doi: 10.1182/blood-2013-10-535443.
  10. Jiang Y, Soong TD, Wang L, et al. Genome-wide detection of genes targeted by Non-Ig somatic hypermutation in lymphoma. PLoS One. 2012;7(7):e40332. doi: 10.1371/journal.pone.0040332.
  11. Khodabakhshi AH, Morin RD, Fejes AP, et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 2012;3(11):1308–19. doi: 10.18632/oncotarget.653.
  12. Mottok A, Woolcock B, Chan FC, et al. Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. Cell Rep. 2015;13(7):1418–31. doi: 10.1016/j.celrep.2015.10.008.
  13. Muhlethaler-Mottet A, Otten LA, Steimle V, et al. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 1997;16(10):2851–60. doi: 10.1093/emboj/16.10.2851.
  14. Roberts RA, Wright G, Rosenwald AR, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood. 2006;108(1):311–8. doi: 10.1182/blood-2005-11-4742.
  15. Balzarotti M, Santoro A. Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? Ann Transl Med. 2020;8(16):1035. doi: 10.21037/atm.2020.04.06.
  16. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–62. doi: 10.1084/jem.20031074.
  17. Miao Y, Medeiros LJ, Li Y, et al. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16(10):634–52. doi: 10.1038/s41571-019-0225-1.
  18. Joos S, Otano-Joos M.I, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood. 1996;87(4):1571–8.
  19. Feuerhake F, Kutok JL, Monti S, et al. NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005;106(4):1392–9. doi: 10.1182/blood-2004-12-4901.
  20. Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004;104(2):543–9. doi: 10.1182/blood-2003-10-3545.
  21. Lees C, Keane C, Gandhi MK, et al. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol. 2019;185(1):25–41. doi: 10.1111/bjh.15778.